Biobusiness on Campus: Commercialization of University-Developed Biomedical Technologies

November 1997

Issue: 52 Food and Drug Law Journal 453-509 (1997)

The university has been the locus of the vast majority of significant biomedical invention. This creative force combined with a competitive industrial setting for pharmaceuticals and other health-related products has facilitated a nexus between the academy and the commercial world. The Bayh-Dole Act aligned the incentives of the university with those of industry, setting off a transformation of old commercialization paradigms and prior university-corporate relationships in the two decades since its enactment. Old impediments to technology transfer, both regulatory and systemic, largely have been removed. A new profession has been born to manage the process: university technology transfer.


FDLI's policy regarding the Food and Drug Law Journal online is: Only the Table of Contents and article abstracts for each issue will be posted to our website. Those visitors wishing to obtain a full text version of a particular article, or a copy of an entire issue, may contact FDLI’s Customer Service Department by e-mail at Your purchase will be processed quickly, and at reasonable rates.

Any questions or concerns regarding this policy should be directed to Michael Levin-Epstein,
FDLI's Editor-in-Chief.